Onco Wiki / Indication

Parathyroid carcinoma · line 2 · Pembrolizumab monotherapy

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy2
Trackaggressive
Linked regimenREG-PEMBROLIZUMAB-MONO
IDIND-PARATHYROID-CARCINOMA-2L-PEMBROLIZUMAB-MSI
TypeIndication
Statusreviewed 2026-07-11
DiseasesDIS-PARATHYROID-CARCINOMA
SourcesSRC-NCCN-NET-2025 SRC-NCCN-THYROID-2025

Notes

STUB pending clinical co-lead signoff (CHARTER §6.1 — dev-mode- exempted draft content). Reuses REG-PEMBROLIZUMAB-MONO (cross-disease generic pembrolizumab-monotherapy regimen already in the KB) and DRUG-PEMBROLIZUMAB rather than creating a duplicate regimen. No parathyroid-carcinoma-specific pembrolizumab trial exists; evidence is extrapolated from the tissue-agnostic MSI-H/dMMR (KEYNOTE-158/164) and TMB-high FDA approvals for solid tumors generally — see DRUG-PEMBROLIZUMAB.regulatory_status.fda.indications_brief and BIO-TMB-HIGH.interpretation_notes (both already in the KB) for that basket-trial context. `sources` cite the two disease-level NCCN guidelines already attached to DIS-PARATHYROID-CARCINOMA as `position: context` (cross-cutting biomarker-driven-therapy principle) rather than `supports`, because neither guideline directly addresses parathyroid carcinoma pembrolizumab use — no new Source stub was authored for KEYNOTE-158 because it is not explicitly named in the Disease narrative supplied for this task. Given the extreme rarity of parathyroid carcinoma, disease-specific prospective trial data is unlikely to ever exist — this Indication documents the best available (tiss...

Used By

Algorithms

Disease

Indication